Vanguard Group’s Filana Therapeutics FLNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$4.7M Buy
2,375,589
+86,066
+4% +$276K ﹤0.01% 3277
2025
Q3
$6.66M Buy
2,289,523
+119,451
+6% +$275K ﹤0.01% 3176
2025
Q2
$3.93M Sell
2,170,072
-272,235
-11% -$484K ﹤0.01% 3294
2025
Q1
$3.66M Sell
2,442,307
-71,178
-3% -$180K ﹤0.01% 3283
2024
Q4
$5.93M Sell
2,513,485
-9,313
-0.4% -$164K ﹤0.01% 3202
2024
Q3
$74.2M Sell
2,522,798
-160,328
-6% -$3.69M ﹤0.01% 2014
2024
Q2
$33.1M Buy
2,683,126
+326,646
+14% +$6.89M ﹤0.01% 2319
2024
Q1
$47.8M Buy
2,356,480
+31,854
+1% +$734K ﹤0.01% 2190
2023
Q4
$52.3M Buy
2,324,626
+56,060
+2% +$1.18M ﹤0.01% 2169
2023
Q3
$37.7M Buy
2,268,566
+18,907
+0.8% +$375K ﹤0.01% 2259
2023
Q2
$55.2M Buy
2,249,659
+12,754
+0.6% +$307K ﹤0.01% 2141
2023
Q1
$54M Buy
2,236,905
+39,980
+2% +$1.11M ﹤0.01% 2143
2022
Q4
$64.9M Buy
2,196,925
+87,062
+4% +$3.13M ﹤0.01% 2038
2022
Q3
$88.2M Buy
2,109,863
+62,151
+3% +$1.68M ﹤0.01% 1869
2022
Q2
$57.6M Buy
2,047,712
+72,983
+4% +$1.84M ﹤0.01% 2130
2022
Q1
$73.3M Sell
1,974,729
-86,090
-4% -$3.65M ﹤0.01% 2108
2021
Q4
$90.1M Buy
2,060,819
+86,537
+4% +$4.54M ﹤0.01% 2045
2021
Q3
$123M Buy
1,974,282
+148,079
+8% +$12.4M ﹤0.01% 1871
2021
Q2
$156M Buy
1,826,203
+52,025
+3% +$2.79M ﹤0.01% 1760
2021
Q1
$79.7M Buy
1,774,178
+190,315
+12% +$7.49M ﹤0.01% 2072
2020
Q4
$10.8M Buy
1,583,863
+310,462
+24% +$2.77M ﹤0.01% 2955
2020
Q3
$14.7M Buy
1,273,401
+152,191
+14% +$686K ﹤0.01% 2597
2020
Q2
$3.45M Buy
1,121,210
+287,169
+34% +$1.3M ﹤0.01% 3257
2020
Q1
$3.43M Buy
834,041
+653,188
+361% +$4.32M ﹤0.01% 3131
2019
Q4
$940K Buy
180,853
+6,178
+4% +$10.7K ﹤0.01% 3659
2019
Q3
$210K Buy
174,675
+7,613
+5% +$9.78K ﹤0.01% 3953
2019
Q2
$202K Sell
167,062
-8,280
-5% -$9.39K ﹤0.01% 3975
2019
Q1
$226K Buy
175,342
+29,818
+20% +$34.2K ﹤0.01% 3901
2018
Q4
$124K Sell
145,524
-73,326
-34% -$84.3K ﹤0.01% 3972
2018
Q3
$221K Buy
218,850
+37,466
+21% +$56.9K ﹤0.01% 3991
2018
Q2
$373K Hold
181,384
﹤0.01% 3874
2018
Q1
$1.29M Buy
181,384
+9,417
+5% +$63.6K ﹤0.01% 3592
2017
Q4
$688K Sell
171,967
-11,921
-6% -$48.1K ﹤0.01% 3688
2017
Q3
$748K Sell
183,888
-4,167
-2% -$14.9K ﹤0.01% 3666
2017
Q2
$774K Sell
188,055
-42,957
-19% -$203K ﹤0.01% 3632
2017
Q1
$1.45M Hold
231,012
﹤0.01% 3477
2016
Q4
$922K Sell
231,012
-30,196
-12% -$140K ﹤0.01% 3581
2016
Q3
$1.83M Buy
261,208
+53,443
+26% +$886K ﹤0.01% 3421
2016
Q2
$3.19M Buy
207,765
+6,686
+3% +$106K ﹤0.01% 3191
2016
Q1
$3.14M Buy
201,079
+2,680
+1% +$34.7K ﹤0.01% 3193
2015
Q4
$2.43M Buy
198,399
+3,363
+2% +$44.5K ﹤0.01% 3314
2015
Q3
$2.5M Buy
195,036
+5,085
+3% +$64.2K ﹤0.01% 3272
2015
Q2
$2.3M Sell
189,951
-4,366
-2% -$59.8K ﹤0.01% 3349
2015
Q1
$2.57M Buy
194,317
+8,412
+5% +$114K ﹤0.01% 3303
2014
Q4
$2.64M Buy
185,905
+2,328
+1% +$40.3K ﹤0.01% 3180
2014
Q3
$5.03M Buy
183,577
+6,810
+4% +$207K ﹤0.01% 2822
2014
Q2
$7.11M Buy
176,767
+10,652
+6% +$394K ﹤0.01% 2672
2014
Q1
$6.4M Buy
166,115
+5,316
+3% +$188K ﹤0.01% 2707
2013
Q4
$5.47M Buy
160,799
+4,629
+3% +$123K ﹤0.01% 2749
2013
Q3
$2.97M Buy
156,170
+3,178
+2% +$55.6K ﹤0.01% 2979
2013
Q2
$2.37M Buy
+152,992
New +$3.23M ﹤0.01% 3005

Other funds holding FLNA

Vanguard Group's FLNA Position: Q4 2025 in Review

Vanguard Group increased its Filana Therapeutics (FLNA) stake by 3.8% in Q4 2025, buying an estimated $276K and bringing the position to 2,375,589 shares worth $4.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3277.

Vanguard Group first reported a position in FLNA in Q2 2013 and has held it in 51 quarters since. The position peaked at $156M in Q2 2021. 107 funds tracked by Wall St. Rank hold FLNA as of Q4 2025.

  • Vanguard Group held 2,375,589 shares of Filana Therapeutics worth $4.7M as of Q4 2025.
  • Vanguard Group bought 86,066 Filana Therapeutics shares in Q4 2025, an estimated $276K.
  • Filana Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3277 holding.
  • Vanguard Group first reported a position in Filana Therapeutics in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's Filana Therapeutics position peaked at $156M in Q2 2021.
  • 107 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.